3 of the Fastest Growing Dermatology CROs

One in four Americans is affected by skin disease, the 18th leading cause of global Disability Adjusted Life Years (DALY). This burden on patients’ quality of life, as well as a growing awareness of the availability of treatments, has led to a significant increase in the global demand for dermatology. The dermatology market is projected growth until 2030 at a CAGR of 6.9%.

Along with the demand for access to dermatologists, there is also a growing requirement for newer, more effective, and more elegant therapies with fewer side effects. The increase in dermatology clinical trials can also be attributed to other factors, including:

  • Increased availability of technology allowing for remote monitoring, such as telemedicine, or for recording patient-reported outcomes.
  • Decentralization of clinical trials.
  • New advances in immunology and precision medicine allowing for further research into diseases such as psoriasis and atopic dermatitis.
  • Rising awareness of clinical trials through social media.

The increase in research in dermatology has led to the subsequent growth of contract research organizations (CROs) that provide services in this therapeutic area as more sponsors and government agencies are outsourcing different aspects of clinical trials. The dermatology CRO market is expected to grow at a CAGR of 8.7% between 2022 and 2032.

How Do CROs Help Dermatology Clinical Trials?

A CRO’s purpose is to provide a place for pharmaceutical, biotech, and medical device companies to outsource the day-to-day management of the clinical trial. Some CROs offer specialized services, while others are full-service providers.

Benefits of working with CROs include:

  • Standard operating procedures have already been established for clinical trials.
  • Availability and implementation of technology to expedite the trial process.
  • Therapeutic expertise.
  • Existing relationships with clinical sites or investigators.
  • Experience and in-depth understanding of regulatory requirements.

Dermatology CROs on the Rise

Several CROs offering services for dermatology clinical trials have experienced a rapid increase in their businesses within the last few years through the adaptation of technology to increase the efficiency of clinical trials by using digital tools and streamlining operations.

Three of the fastest-growing dermatology CROs include:

Dermatology CRO #1: Curebase

Curebase is a full-service CRO established in San Francisco, California, in 2012. End-to-end CRO services provided by Curebase include study design and protocol development, site identification and activation, software platform configuration and training, recruitment and retention, and project management and monitoring. Through the use of technology like ePRO, telemedicine, wearables, eSource, and EDC, Curebase offers the establishment of virtual and hybrid sites to build decentralized clinical trials and reach more patients through in-home, community-based, and site-based care. Curebase also specializes in running diagnostic studies.

Curebase employs 138 people, increasing its employee count by 283% since last year. The annual revenue is US$14.1 million per year. Curebase completed Series B funding in May of 2022, increasing funding by US$40 million. It also gained 10 more investors, most recently including Gilead Sciences.

Dermatology CRO #2: Vial Health Technology

Vial is a next-generation, tech-enabled clinical research organization (CRO) that provides global end-to-end clinical trial services. Founded in San Francisco, California, in 2020, Vial dermatology CRO’s mission is to reimagine clinical trials by disrupting the traditional research model through a powerful technology platform in one connected system. The Vial CRO’s technology platform is fully encrypted and compliant with the standards of 21 CRF Part 11, HIPAA, and GDPR, and streamlines the clinical trial by integrating  EDC, eSource, and ePRO.

Vial CRO’s number of employees has grown by 488% to a total of 125 in the last year. The CRO completed its Series B funding in November of 2022, increasing its investors by 13 and funding by USD 67 million, with a total of over $100 million. Vial’s estimated annual revenue is US$27 million per year and US$270,000 per employee.

Dermatology CRO #3: Biorasi

Biorasi is a global CRO established in 2002 in Aventura, Florida. With offices around the world, Biorasi provides support for clinical trials in the Americas, Europe, and APAC. With over 15 years of experience in dermatology, Biorasi has established expertise in the diseases spaces of atopic dermatitis, plaque psoriasis, and rare dermatology diseases. With the use of digital technology to allow for decentralized trials and remote patient engagement, Biorasi’s central goal is to maximize speed-to-market.

Biorasi has increased its employees by 28% to 658 employees in the last year. The current estimated revenue is US$132.3 million per year.

Run your trials faster with a trusted CRO partner

Vial dermatology CRO uses best-in-class technology to minimize human error, and streamline workflow from start to finish. This allows for the delivery of efficient onboarding, enrollment, communication, data collection, and activation of clinical sites within 30 days

The availability of experts in the ClinOps team, project managers and clinical research associates (CRAs) with expertise in dermatology clinical trials, industry leaders on the scientific advisory board, and a strong network of investigators ensures faster and higher quality trials.

Vial offers fixed-price agreements with zero change orders, which allows for further efficiency in the trial process. Get in touch today to learn more about how we can help with your dermatology clinical trial. Connect with us today to learn how we can help you.

Contact Us

By submitting, you are agreeing to our terms and privacy policy
This field is for validation purposes and should be left unchanged.